Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women

被引：17
|
作者：
Kittaneh, Muaiad [1 ]
Gluck, Stefan [1 ]
机构：
[1] Univ Miami, Leonard M Miller Sch Med, 1475 NW 12th Ave,Suite 3310, Miami, FL 33146 USA
来源：
BREAST CANCER-BASIC AND CLINICAL RESEARCH | 2011年 / 5卷
关键词：
aromatase inhibitor; breast cancer; exemestane; disease-free survival; tamoxifen;
D O I：
10.4137/BCBCR.S6234
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Exemestane is an irreversible inhibitor of the aromatase enzyme, which is a key component in the production of estrogen. The majority of breast cancers are sensitive to the proliferative effects of estrogen. Exemestane is approved for the adjuvant treatment of postmenopausal women with breast cancer after 2 to 3 years of tamoxifen therapy, based on a 32% improvement in disease-free survival compared with 5 years of tamoxifen alone (P < 0.001). Exemestane has also shown clinical benefits as an upfront therapy. The safety profile of exemestane shares some side effects with tamoxifen (hot flashes and arthralgia), but is not associated with an increased risk of endometrial cancer or thromboembolic events. This review will discuss in detail the efficacy and safety of exemestane in early breast cancer.
引用
收藏
页码：209 / 226
页数：18
相关论文
共 50 条
  • [1] Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane
    Macpherson, Iain R. J.
    Lindsay, Colin
    Canney, Peter
    [J]. BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 59 - 70
  • [2] Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
    Lisa Hutchinson
    [J]. Nature Clinical Practice Oncology, 2004, 1 : 24 - 25
  • [3] Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
    Hutchinson, Lisa
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2004, 1 (01): : 24 - 25
  • [4] Adjuvant treatment of breast cancer with exemestane
    Kunkler, IH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (01): : 100 - 100
  • [5] Exemestane in adjuvant treatment of early breast cancer in postmenopausal women: results of a UK cost-effectiveness model
    不详
    [J]. EJC SUPPLEMENTS, 2006, 4 (02): : 151 - 151
  • [6] Exemestane for primary prevention of breast cancer in postmenopausal women
    Zhang, Yang
    Simondsen, Katherine
    Kolesar, Jill M.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (16) : 1384 - 1388
  • [7] Exemestane for Breast-Cancer Prevention in Postmenopausal Women
    Goss, Paul E.
    Ingle, James N.
    Ales-Martinez, Jose E.
    Cheung, Angela M.
    Chlebowski, Rowan T.
    Wactawski-Wende, Jean
    McTiernan, Anne
    Robbins, John
    Johnson, Karen C.
    Martin, Lisa W.
    Winquist, Eric
    Sarto, Gloria E.
    Garber, Judy E.
    Fabian, Carol J.
    Pujol, Pascal
    Maunsell, Elizabeth
    Farmer, Patricia
    Gelmon, Karen A.
    Tu, Dongsheng
    Richardson, Harriet
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (25): : 2381 - 2391
  • [8] EXEMESTANE PREVENTS INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN
    不详
    [J]. CANCER DISCOVERY, 2011, 1 (02) : 96 - 96
  • [9] The effects on lipids of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer
    Gonnelli, S.
    Montagnani, A.
    Cadirni, A.
    Caffarelli, C.
    Montomoli, M.
    Campagna, M. S.
    Petrioli, R.
    Del Santo, K.
    Cuda, C.
    Nuti, R.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 409 - 409
  • [10] Exemestane following tamoxifen in postmenopausal women with primary breast cancer
    Mouridsen, HT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) : 3833 - 3834
12345